Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|July 2, 2019

Amicus Therapeutics Enters Strategic Manufacturing Collaboration with Thermo

Amicus Therapeutics has entered into a strategic gene therapy development and manufacturing collaboration with Brammer Bio, which is a part of Thermo Fisher Scientific.

Biotech company, Amicus Therapeutics, has entered into a strategic gene therapy development and manufacturing collaboration with Brammer Bio, which is a part of Thermo Fisher Scientific, it was announced in a July 1, 2019 press release.

Under the terms of the agreement, Thermo will provide Amicus with immediate clinical and commercial manufacturing capabilities and capacity for its intrathecal AAV Batten disease gene therapy programs. Additionally, Amicus stated that it has established a network for plasmid supply through multiple long-term supply agreements from plasmid suppliers that it will use to support the progression of all current gene therapy pipeline programs.

“As we advance one of the industry’s leading gene therapy pipelines, our partnership with Brammer Bio, now part of Thermo Fisher, is a significant next step in fulfilling our manufacturing strategy so that we can deliver novel gene therapies to more people living with rare genetic diseases as quickly as possible, especially in devastating diseases like Batten’s, where time is of the essence,” said John F. Crowley, chairman and chief executive officer of Amicus, in a press release. 

“We are thrilled to begin working with Amicus and to contribute to the successful development of their gene therapy pipeline,” added Chris Murphy, vice-president and general manager, viral vector services at Thermo Fisher Scientific. “We see this as a strong strategic relationship to enable manufacturing of a deep gene therapy pipeline across various stages of development for people with devastating genetic diseases. These therapies have the potential to transform patients’ lives and, as an organization, we are delighted to support partners such as Amicus as they advance tomorrow's potential medicines.”

Source: Amicus Therapeutics

 


Related to this article

The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.